D2C7-IT With Atezolizumab for Recurrent Gliomas

NCT04160494 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma

Interventions

DRUG: D2C7-IT (6920 ng/mL via convection-enhanced delivery)
DRUG: Atezolizumab (1200 mg every three weeks)
DRUG: D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)

Sponsor

Darell Bigner

Collaborators

[object Object]
[object Object]
[object Object]